Hanlin Gao - May 27, 2025 Form 4 Insider Report for Fulgent Genetics, Inc. (FLGT)

Role
Chief Scientific Officer
Signature
/s/ Paul Kim as Attorney-in-Fact
Stock symbol
FLGT
Transactions as of
May 27, 2025
Transactions value $
-$21,339
Form type
4
Date filed
5/28/2025, 04:16 PM
Previous filing
May 2, 2025
Next filing
Jun 3, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gao Hanlin Chief Scientific Officer C/O FULGENT GENETICS, INC., 4399 SANTA ANITA AVENUE, EL MONTE /s/ Paul Kim as Attorney-in-Fact 2025-05-28 0001684532

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FLGT Common Stock Sale -$7.88K -383 -0.04% $20.58 963K May 27, 2025 Direct F1, F2
transaction FLGT Common Stock Sale -$13.5K -656 -0.07% $20.52 962K May 27, 2025 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023.
F2 The shares were sold in multiple transactions at prices ranging from $20.41 to $20.79, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F3 The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024.
F4 The shares were sold in multiple transactions at prices ranging from $20.445 to $20.56, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.